Disease: personality disorders

PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction

mycolabadmin

This Polish study surveyed nearly 2,500 recreational drug users about their substance use patterns and mental health. The survey found that marijuana is the most commonly used illicit drug, but worryingly, most users don’t test what they’re taking or measure doses carefully. The study also revealed increasing use of mephedrone and other stimulants that are sending more people to hospitals, while interest in psychedelics is declining. Importantly, more people are now seeing psychiatrists and being honest about their drug use.

Read More »

Psychedelics and the treatment of eating disorders: considerations for future research and practice

mycolabadmin

As researchers explore using psychedelic drugs like psilocybin to treat eating disorders, this article outlines important safety considerations and ethical guidelines needed before widespread use. While some early trials show promise, significant concerns exist including physiological risks (heart problems, nausea), psychological challenges, potential for therapist misconduct, and medication interactions. The authors recommend rigorous research designs, better inclusion of diverse populations, and careful integration of psychedelics with proven eating disorder treatments.

Read More »

Implementing psychedelic-assisted therapy: History and characteristics of the Swiss limited medical use program

mycolabadmin

Switzerland operates a unique program allowing controlled use of psychedelics (LSD, psilocybin) and MDMA to help patients with serious mental health conditions that haven’t responded to standard treatments. Since 2014, about 100 doctors have treated 700+ patients with these substances as part of therapy sessions. The program requires careful patient screening, informed consent, and outcome reporting, with patients typically receiving 2-4 treatments over 12 months. Most patients showed significant improvement in their conditions, though some experienced side effects like nausea or headaches.

Read More »

A taxonomy of regulatory and policy matters relevant to psychedelic-assisted therapy in Australia

mycolabadmin

Australia has recently approved psilocybin and MDMA for treating severe depression and PTSD when used with professional therapy support. This paper creates a comprehensive guide outlining all the regulatory, professional, and safety considerations needed to safely deliver these treatments in clinical settings. The researchers interviewed 11 experts and reviewed existing research to identify 102 specific matters that need clear guidelines, such as what qualifications therapists need, where treatments can be delivered, how patients should be screened, and what safety measures are essential.

Read More »

Lower-dose psycholytic therapy – A neglected approach

mycolabadmin

This review examines psycholytic therapy, a method using lower doses of LSD or psilocybin combined with ongoing psychotherapy to help people process psychological conflicts and trauma. Developed in Europe during the 1960s-1970s and used successfully at over 30 clinics, this approach was largely abandoned when psychedelics became illegal but is now being reconsidered. Historical research shows it was effective for anxiety, depression, and personality issues in treatment-resistant patients, with safety profiles comparable to conventional therapy.

Read More »
Scroll to Top